Operator
Hello, everyone. Thank you for joining us and welcome to the Innate Pharma first half 2026 business update and financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Stephanie Cornyn, Vice President, Investor Relations, Communication, and Commercial. Stephanie, please go ahead.
Good morning and good afternoon, everyone. Thank you for joining us for Innate Pharma's first half, 2026, Business Update and Financial Results Conference Call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. To briefly cover today's agenda, our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. Marcus Jensen, Our chief medical officer and Yanis Morel, our chief operating officer, will then take us through updates on Lacutamab, IPH4502, Monalizumab, and our preclinical ADC pipeline. Frédéric Lombard, our chief financial officer, will then review our financial results. Jonathan will return for our upcoming catalysts and closing remarks before we open the call for Q&A. With that, I will now hand it over to Jonathan.
Thank you, Stephanie. Good morning to those joining from the U.S. and good afternoon to our European participants. Turning to slide five, the first half of 2026, together with development since the end of the period, has been marked by important progress across our focus portfolio. Starting with Locutumab, in August, we announced our strategic partnership with SOBI to advance the program in T-cell lymphoma. As announced yesterday, that partnership is now effective following the closing of the deal, and the Telemac 3 Phase 3 has been initiated. We are targeting the first patient in the study in Q1, 2027, as we work toward a filing for accelerated approval in cesary syndrome in H2, 2027. For IPH4502, as announced in July, we completed phase one dose escalation and cohort enrichment enrollment and have seen preliminary anti-tumor activity, including objective responses in post-EV urophilial cancer, as well as in non-small cell lung cancer and head and neck cancer. With a favorable safety profile observed to date, we will share initial Phase I dose escalation data at the EORTC-NCI-AACR meeting on November 18, 2026, in Barcelona. Turning to monolizumab, enrolment in the Pacific 9 Phase 3 study has been completed, and we continue to expect the Phase 3 readout in the second half of 2026. Financially, our position has been strengthened by the $75 million SOBI upfront payment associated with the closing of the deal and the $30 million equity financial. Together, these are expected to extend our projected cash runway through the end of the first quarter of 2028. Taken together, we believe these developments position an aid for several important catalysts in the second half of 2026. Let me start with lacutamab. Lacutamab is our anti-CUR3-DL2 antibody being developed in cutaneous T-cell lymphoma, or CTCL. Turning to slide 7, as I mentioned, in August, we announced a strategic partnership with SOBI to license lacutamab in T-cell lymphoma. The transaction has now closed. TELEMAC3, our confirmatory Phase 3 study in CTCL, has been initiated with the first patient expected in the first quarter of 2027. INATE will conduct the Phase 3 study, and we will file for accelerated approval in cesarean syndrome based on the existing Phase 2 TELEMAC data. Upon the potential accelerated approval, SOBI will receive exclusive global rights to commercialize locutum app. Following positive phase three results, SOBI will be eligible to obtain full global development rights. Under the terms of the agreement, the transaction includes a 75 million Upfront payment up to $40 million in near-term milestones connected to SESRI syndrome, and up to an additional $465 million related to Sobeys' option to obtain full development rights and future regulatory and commercial milestones. The agreement also includes tiered, double-digit royalties on future net sales. I'll now hand it over to Marcus to review the regulatory and development path forward. Marcus.
Thank you, Jonathan. Lekwutamap is now progressing towards Phase 3 telemark initiation and planned accelerated approval filing. So from a regulatory and development perspective, the path forward is well-defined. We have FDA clearance to proceed with Telomag3, which now has been initiated with the first patient expected in the first quarter of 2027. The study includes a confirmatory cohort in cesare syndrome and a registrational cohort in the causes phongoitis. The existing Phase II Telomag data are intended to support an accelerated approval filing in cesare syndrome once Telomag III is underway, with the filing currently planned for the second half of 2027. As a reminder, LACUTA-MAP has received breakthrough therapy designation from the FDA for relapsed or refractory scissory syndrome, as well as fast-track designation from the FDA, prime designation from the EMA, and an orphan drug status in both United States and Europe. So, with the regulatory pathway established and the SOBI partnership now effective, our focus is on advancing telemetry towards first patient enrollment, first order 2027. Turning the slide, please. I now move to IPH 4502, our differentiated negatin-4-excepticon ADC, IPH45 was designed to address some of the key limitations of the first generation of N4ADCs. The molecule combines an exatecan topoisomerase-1 payload with our proprietary stable linker and a high-affinity N4 antibody that binds non-overlapping epitope compared with N4ADC. We believe these features provide an important point of differentiation as the Nectin-4-ADC landscape continues to evolve. Importantly, we are now beginning to see that COFIL translate clinically and have observed preliminary anti-tumor activity with objective responses in heavily pretreated patients, The safety profile observed to date has been favorable with limited hematological toxicity. We've completed dose escalation in July and are broadly tracking in line with our expectations across expansion cohorts with approximately 15 patients enrolled in both post-TB urothelial cancer, head and neck cancer, and somewhat lower enrollment in non-small cell lung cancer cohort. Data cleaning is ongoing, and we look forward to presenting the initial Phase I dose escalation data set at the EORTC-NCI-AACR symposium on November 18th, 26th. Next slide, please. Our area of particular interest for IPH45 is urothelial cancer following prior EV treatment. While EV plus pembrolizumab A significant change to the treatment landscape. Most patients progress within two years, and there remains no established second-line standard treatment after progression of this regime. Against that backdrop, the preliminary activity we have observed with IPH 45.2 in heavily pretreated post-TB patients, including objective responses, is encouraging. These remain early Phase I observations, and the upcoming dataset will help us to determine how to best advance the program. Slide 12, please. I now move forward to Monalithumab, which is our NKG2A antibody being co-developed with AstraZeneca in non-small cell lung cancer. Specific 9 is a randomized phase 3 trial with unresectable stage 3 non-small cell lung cancer patients who have not progressed following a definitive platinum-based concurrent chemoradiotherapy. Study enrolled 1051 patients and compares to Duvalumab plus Oleglumab, Duvalumab plus Monalizumab, And Duvalumab plus placebo has a control with progression pre-survival as the primary endpoint. The program is supported by three earlier phase 2 studies in Mons-Mons and Lung Cancer, including COST, NEOCOST and NEOCOST2. With enrollment complete, phase 3 data remain expected in the second half of 2026. I now hand over to Yannis to briefly review the economics of our partnership with AstraZeneca.
Thank you, Marcus. As a reminder, under our Monalizumab partnership with AstraZeneca, we have received up-to-date 450 million, and the additional potential milestones in the agreement are up to 825 million, together with double-digit royalties outside Europe and 50% profit sharing in Europe. Turning to slide 15, I'll move now to our next generation ADC pipeline. Beyond IPH4502, we are using our internal capabilities and technology to build a broad portfolio of differentiated ADC candidates. Turning to slide 16, leveraging our antibody discovery and engineering expertise, we have built a comprehensive ADC platform to develop a portfolio of next Next-generation ADCs designed to overcome the limitation of the current ones. Building on IPH4502 linker, which stability in patients is demonstrated by our emerging clinical data, we are developing a drug candidate portfolio around three approaches. First, dual targeted bispecifics ADCs to address tumor antigen heterogeneity and to expand addressable indication compared to single tumor antigen targeting. Second, bispecific ADCs with enhanced internalization to unlock the activity in antigen low-expressing tumors. And finally, dual payload ADCs using complementary mechanism of action to overcome resistance. I'll now hand over to Frédéric for our financial results.
Thank you, Yanis. I'll now provide a brief overview of our financial position for the first half of 2026. Turning to slide 18. So out of June 30, 2026, our cash equivalent and financial asset were amounting for 21.4 million euro. That balance does not include the 75 million USD, so the upfront payment equivalent to 65 million euro, Nor the proceeds from the $30 million equity offering. The offering represents $30 million on gross proceeds or approximately $28 million in expected net proceeds. The primary use of proceeds is the continued clinical development of EPH 4502, the advancements of our pre-clinical IDC portfolio, and as well as general corporate purposes. Together with the SOBI upfront payment, these proceeds are expected to extend our cash runway through the end of the first quarter of 2028. I'll now hand over to Jonathan.
Thank you, Frederic. Moving to slide 20 and turning to our key catalysts for the remainder of 2026. For Locutumab, following closing of the strategic partnership with SOBI, Telemac3 has been initiated with the first patient planned for the first quarter of 2027, followed by a planned filing for accelerated approval in the second half of 2027. For IPH4502, dose escalation enrollment is complete with preliminary anti-tumor activity and a favorable safety profile observed today. We will report initial Phase I dose escalation data at the EORTC-NCI-AACR meeting on November 18, 2026. And for Monoluzumab, Pacific 9 enrollment is complete with the Phase 3 readout expected in the second half of this year. So we have three important near-term catalysts across our focus portfolio, together with a strengthened financial position that supports our continued execution of these priorities. With that, operator, we are ready to open the call for questions.
Operator
We will now begin the question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Dana Graybosch with Leerink Partners. Your line is open, Dana. Please go ahead.
Hey, morning, everyone. Congrats on the update. So just one for me. I got Bill on for Dana. So we've seen the prior ExoTECAN-based ADC show some pretty good activity in the post-pads-dev setting, but it did have some pretty high heme toxicities. And so can you talk about IPH45's stable linker design and sort of what gives you confidence you won't see the same sort of issues? Thank you.
Thank you for the question. Maybe, Yanis, you can take that one.
Yeah, maybe I can start and let Marcus comment. I mean, we have worked on the design of the linker and based on what we have seen at ASCO published by others with their own linker. It seems that the stability of our linker that we have seen in preclinical models, including in non-human primates, seems to be translated into the human situation, leading to a very limited release of a free payload, which is one of the reasons of the systemic pathological toxicity of some ADCs.
Yeah. What we can add is the LILI data that have been released recently actually state that based on their own data that have seen in the trial. So the instable linker was used as an explanation for the hematologic toxicity in this data set.
Operator
Your next question comes from the line of Jeet Mukherjee with US Bancorp BTIG. Your line is open, Jeet. Please go ahead.
Great. Good morning, and thanks for taking the question. So, pending, you know, an accelerated approval there, could you speak to the potential for frontline off-label use for lacutumab and cesare syndrome, given that seems to be the case with mogulizumab? And I have a follow-up question.
Yeah, maybe I will take that question, Jeet. So, our expectation is that lacutumab will be listed in the NCCN guidelines following the accelerated approval for both cesarean syndrome and for mycoses fungoides. I think with that listing, it seems to leave it open for physicians to be able to use the product across the different lines of therapy. So our expectation based on the safety profile of lacutumab, which is pretty benign, we expect that you will see some off-label usage in the first-line setting. And so, yeah, I mean, I think there's an expectation you will see that. And also, despite the fact that the accelerated approval will be in cesare syndrome, there will also be an expectation based on the potential listing in the NCCA guidelines for mycosis fungoides that you will also see usage in MF.
Hopefully that answers your question. Great. I appreciate that. Maybe just two other quick follow-ups. Just any initial thoughts on pricing? Do you think you could price at a premium to mogulizumab? And then separately on Pacific 9, in terms of just the update format, anticipate perhaps a press release at minimum from AstraZeneca, but will Innate have their own press release and analyst call as well? Thank you.
Yeah, so in terms of pricing, we have completed pricing research in the U.S., which was conducted by ZS Associates, and what we were able to establish with U.S. payers was that we can price lacutumab between $500,000 and $625,000 per patient per annum, And that will be supported by our clinical data and the NCCN listing. So there is an expectation here that you would be able to achieve premium pricing, particularly in an indication like cesarean syndrome, with a relatively low incidence, and then be able to carry that forward into the mycosis fungoides indication, which is a larger indication, but still an orphan disease. So that's pricing. And then with respect to Pacific 9, you're correct. The expectation is that there will be a press release from AstraZeneca when the results are available. And we would also look to press release that as well and potentially do some analyst calls following the availability of that primary endpoint data.
Hopefully that answers the question.
Operator
The next question will be read by Stephanie Cornyn. Stephanie, please go ahead.
Yes. So we have a question from Clemence Steers from Stephen. The first question is, as those escalation and cohort expansion and enrollment are now complete, should we expect the initial ENA data set to be primarily a safety pharmacology update or mature enough to inform subsequent development decision?
So, Marcus, maybe you can take that question.
Yeah, the question is almost the answer. So this is out of 11 different indications and 76 patients, so we are expecting to see relevant and informative safety data, and we are also expecting response data from patients, and this will inform our next steps. We need to fully run the tables, and we will review and disclose that as proposed on the INA meeting.
Thank you. And there is another question from Clemence. With the strength and balance sheet following the recent financing, how far along the development path could you advance IPH 4502 on your own?
So maybe I can take that. So I think you're all aware that we did a small equity raise of 30 million euros a couple of weeks ago. The rationale behind that equity raise was to be able to progress seamlessly into the next steps for 4502. So we're well positioned now to be able to move into the next steps, whatever that will be, And the data will dictate what that is, whether it's dose optimization. And we're equipped to be able to do that. If we would need to broaden the program, if the data supports going to potentially additional tumor types, then that would require additional funding to be able to conduct multiple dose optimizations across different tumor types. But at least for the initial steps, we're funded to be able to take those steps and take the product forward seamlessly into dose optimization. Hopefully, that answers the question again.
Operator
We have now reached the end of the Q&A session. I will turn the call back to Jonathan Dickinson, CEO, for closing remarks.
Thanks. So thank you very much, everybody, for joining us today for our update following our H1 results. We look forward to updating you as we progress through the important catalysts that we outlined today, which come across the remainder of the year. So thank you for your time, and see you soon.
Operator
This concludes today's call. Thank you for attending. You may now disconnect. Good.
